Skip to main content

Annunciati i Late-Breaking Clinical Trials di ACC.21

A cura di Redazione By 9 Marzo 2021Febbraio 22nd, 2022No Comments
News
Late-Breaking ACC.21

Sono stati annunciati i Late-Breaking Clinical Trials di ACC.21, il meeting annuale dell’American College of Cardiology in programma dal 15 al 17 maggio in formato virtuale.

ACC.21

Late-Breaking Clinical Trials I

American College of Cardiology / Journal of the American College of Cardiology
Sabato 15 maggio | 15:00 – 16:00:

  • PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction
  • ADAPTABLE Study: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
  • LAAOS III: The Left Atrial Appendage Occlusion Study III
Late-Breaking Clinical Trials II

American College of Cardiology / Journal of the American Medical Association
Domenica 16 maggio | 14:00 – 15:30:

  • Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 – Main Results From The DARE-19 Randomized Trial
  • VOYAGER PAD Trial: Reductions In Total Ischemic Events With Rivaroxaban In Patients With Symptomatic Pad After Revascularization
  • STAMPEDE Trial: Surgical Versus Medical Treatment Of Type 2 Diabetes: 10-year Results of the Stampede Randomized Clinical Trial
  • REHAB-HF Trial: A Novel Physical Rehabilitation Intervention For Older Patients With Acute Decompensated Heart Failure
  • Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk
  • PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
Late-Breaking Clinical Trials III

American College of Cardiology / New England Journal of Medicine
Domenica 16 maggio | 16:45 – 18:15:

  • The FLOWER-MI Randomized Trial: Fractional Flow Reserve-guided Versus Angio-guided Multivessel Revascularization In ST-Elevation Myocardial Infarction Patients
  • A Prospective, Multicenter, Randomized, Open-label Trial To Compare Efficacy And Safety Of Clopidogrel Versus Ticagrelor In Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention
  • Host Exam Randomized Controlled Trial: Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention
  • Late Outcomes Of A 1-hour High Sensitivity Troponin T Protocol In Suspected Acute Coronary Syndromes: A Randomized Clinical Trial
  • Randomized Sham-controlled RADIANCE-HTN TRIO Trial: Endovascular Ultrasound Renal Denervation To Treat Hypertension Resistant To A Fixed Dose Triple Medication Pill
Late-Breaking Clinical Trials IV

Lunedì 17 maggio | 14:00 – 15:30

  • Benefits Of Sodium Glucose Co-transporter-1/2 Inhibition With Sotagliflozin Across The Full Spectrum Of Ejection Fraction, Including Heart Failure With Preserved Ejection Fraction
  • Primary Results of the Connect-hf Randomized Clinical Trial: Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure
  • Results of the LIFE Trial: Sacubitril/Valsartan (LCZ696) In Patients With Advanced Heart Failure And Reduced Ejection Fraction
  • Pirfenidone In Heart Failure With Preserved Ejection Fraction
  • Secondary Analysis From GALACTIC-HF: Impact Of Ejection Fraction On The Therapeutic Effect Of Omecamtiv Mecarbil In Patients With Heart Failure And Reduced Ejection Fraction
Late-Breaking Clinical Trials V

Lunedì 17 maggio | 16:45 – 18:15

  • Therapeutic Hypothermia Following Out-Of-Hospital Cardiac Arrest: A Randomized Trial Comparing Mild And Moderate Therapeutic Hypothermia
  • Prague OHCA Study: Hyperinvasive Approach In Refractory Out-of-Hospital Cardiac Arrest: An Open-label Randomized Controlled Trial
  • RAFT-AF: A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial In Patients With Heart Failure And High Burden Atrial Fibrillation
  • Acute Alcohol Consumption And Discrete Atrial Fibrillation Events
  • Finerenone And New Onset Of Atrial Fibrillation Or Flutter In Patients With Chronic Kidney Disease And Type 2 Diabetes